lassedesignen / Shutterstock.com
The link between marketing authorisations and patents in Mexico needs to be reformulated to better protect second medical use patents, argues Soledad Betanzos-Lara of Goodrich, Riquelme y Asociados.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Soledad Betanzos-Lara, Goodrich, Riquelme y Asociados, OFEPRIS, IMPI, patent, second medical use patents,
